Trial Profile
An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Human skin replacement (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions; First in man
- Sponsors Stratatech
- 08 Oct 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2018 According to a Mallinckrodt media release, the first patient has been enrolled in this trial.